The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | PREVENT: preventive HIPEC in combination with perioperative FLOT for gastric cancer
Thorsten O. Goetze, MD, University Cancer Center Frankfurt, Frankfurt, Germany, talks on the Phase III PREVENT trial (NCT04447352), a trial-in-progress investigating preventive Hyperthermic IntraPEritoneal Chemoperfusion (HIPEC) in combination with perioperative FLOT (fluoruracil, leucovorin, oxaliplatin and docetaxel) versus FLOT alone for resectable diffuse-type gastric and gastroesophageal junction type II/III adenocarcinoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
